DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Telmisartan (Drug); Amlodipine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Study to investigate the steady state pharmacokinetics of 80 mg telmisartan alone and in combination with repeated doses of 10 mg amlodipine

Clinical Details

Official title: Pharmacokinetics of Repeated Oral Doses of 80 mg Telmisartan (Micardis) at Steady State Alone and in Combination With Repeated Oral Doses of Amlodipine 10 mg (Norvasc) at Steady State. A Two-way Crossover, Open, Randomised Design Study

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Area under the concentration-time curve of telmisartan in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)

Maximum measured concentration of telmisartan in plasma at steady state over a uniform dosing interval τ (Cmax,ss)

Secondary outcome:

AUCτ,ss for amlodipine

Cmax,ss for amlodipine

Maximum measured concentration of the analyte in plasma (Cmax)

Time from dosing to maximum measured concentration on plasma (tmax)

Area under the plasma concentration-time curve over a uniform dosing interval τ after administration of the first dose; corresponds to AUC0-24h (AUCτ,1)

Pre-dose concentration of the analyte in plasma immediately before the administration of the next dose N (Cpre,N)

Time from last dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)

Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

Terminal rate constant in plasma at steady state (λz,ss)

Terminal half-life of the analyte in plasma at steady state (t1/2, ss)

Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)

Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)

Apparent volume of distribution of the analyte in plasma at steady state after extravascular multiple dose administration (Vz/F,ss)

Accumulation ratio of the analyte in plasma based on AUC over a uniform dosing interval after the first and last doses (RA, AUC)

Accumulation ratio of the analyte in plasma based on Cmax over a uniform dosing interval after the last and first doses (RA,Cmax)

Number of subjects with adverse events

Assessment of tolerability by investigator on a 4-point scale

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests 2. Age ≥18 and Age ≤50 years 3. BMI ≥18. 5 and BMI ≤29. 9 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation Exclusion Criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Surgery of the gastrointestinal tract (except appendectomy) 5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts 7. Chronic or relevant acute infections 8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 9. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 10. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/corrected QT interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial 11. Participation in another trial with an investigational drug within two months prior to administration or during the trial 12. Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day) 13. Inability to refrain from smoking on trial days 14. Alcohol abuse (more than 60 g/day) 15. Drug abuse 16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 17. Excessive physical activities (within one week prior to administration or during the trial) 18. Any laboratory value outside the reference range that is of clinical relevance 19. Inability to comply with dietary regimen of trial site 20. Any history of relevant low blood pressure 21. Supine blood pressure at screening of systolic <110 mm Hg and/or diastolic <60 mm Hg 22. History of urticaria For female subjects: 23. Pregnancy or planning to become pregnant within 2 months of study completion 24. Positive pregnancy test 25. No adequate contraception e. g. sterilisation, intrauterine device, have not been using a barrier method of contraception for at least 3 months prior to participation in the study 26. Are not willing or are unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial 27. Chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception 28. Partner is unwilling to use condoms 29. Lactation period

Locations and Contacts

Additional Information

Starting date: May 2006
Last updated: October 6, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017